DNTH Stock Overview
Dianthus Therapeutics, Inc., a clinical-stage biotechnology company, develops complement therapeutics for patients with severe autoimmune and inflammatory diseases.
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
Dianthus Therapeutics, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$24.01 |
| 52 Week High | US$33.77 |
| 52 Week Low | US$6.58 |
| Beta | 0 |
| 1 Month Change | -10.04% |
| 3 Month Change | 18.86% |
| 1 Year Change | n/a |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | 118.27% |
Recent News & Updates
Recent updates
Shareholder Returns
| DNTH | US Biotechs | US Market | |
|---|---|---|---|
| 7D | 14.4% | 0.5% | -0.7% |
| 1Y | n/a | 1.2% | 22.8% |
Return vs Industry: Insufficient data to determine how DNTH performed against the US Biotechs industry.
Return vs Market: Insufficient data to determine how DNTH performed against the US Market.
Price Volatility
| DNTH volatility | |
|---|---|
| DNTH Average Weekly Movement | 10.8% |
| Biotechs Industry Average Movement | 11.6% |
| Market Average Movement | 6.1% |
| 10% most volatile stocks in US Market | 16.7% |
| 10% least volatile stocks in US Market | 3.0% |
Stable Share Price: DNTH's share price has been volatile over the past 3 months.
Volatility Over Time: DNTH's weekly volatility (11%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2019 | 53 | Marino Garcia | dianthustx.com |
Dianthus Therapeutics, Inc., a clinical-stage biotechnology company, develops complement therapeutics for patients with severe autoimmune and inflammatory diseases. It is developing DNTH103, a monoclonal antibody, which is in Phase 2 clinical trial, for the treatment of generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy. Dianthus Therapeutics, Inc. was founded in 2019 and is headquartered in New York, New York.
Dianthus Therapeutics, Inc. Fundamentals Summary
| DNTH fundamental statistics | |
|---|---|
| Market cap | US$661.22m |
| Earnings (TTM) | -US$43.55m |
| Revenue (TTM) | US$2.83m |
249.3x
P/S Ratio-16.2x
P/E RatioIs DNTH overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| DNTH income statement (TTM) | |
|---|---|
| Revenue | US$2.83m |
| Cost of Revenue | US$0 |
| Gross Profit | US$2.83m |
| Other Expenses | US$46.38m |
| Earnings | -US$43.55m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -1.48 |
| Gross Margin | 100.00% |
| Net Profit Margin | -1,541.22% |
| Debt/Equity Ratio | 0% |
How did DNTH perform over the long term?
See historical performance and comparison